Potential therapeutic compounds against hypercholesterolemia: an in-silico analysis
Article Sidebar
Main Article Content
Abstract
Objective: To identify and evaluate potential alternative compounds targeting HMG-CoA reductase through in-silico methods for the treatment of hypercholesterolemia, aiming for improved safety and pharmacokinetic profiles compared to existing statins.
Methods: We employed in-silico analysis to identify molecules that can bind to drug target of statins; 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA reductase) and could be used as potential drugs against hypercholesterolemia and with fewer side effects. Molecular docking analysis of the eight compounds [25-Hydroxycholesterol (25HC), TAK-715, Flufenamic acid, Piceatannol, Retinol, Nortriptyline hydrochloride, Losmapimod and AG555 (tyrphostinb46)] was performed against HMG-CoA to probe the ligand protein interaction profile. Subsequently, molecular dynamics simulation was performed by Maestro in Schrodinger Suite to study the dynamic behavior of each compound. Molinspiration server was utilized for the in-silico drug-likeness and bioactivity while the SwissADME and admetSAR were used for ADMET analysis.
Results: All eight repurposed compounds showed favorable binding interactions with HMG-CoA reductase and demonstrated good ADMET properties, including blood-brain barrier permeability, CYP2D6 binding, intestinal absorption, and Caco-2 permeability. TAK-715 and Tyrphostin b46 exhibited the lowest docking scores and stable molecular dynamics, indicating strong binding affinity. Piceatannol showed the most stable ligand-protein complex in RMSF analysis. Drug-likeness and toxicity assessments confirmed the acceptable pharmacokinetic profiles. Overall, TAK-715, Tyrphostin b46, Losmapimod, and Flufenamic acid emerged as the most promising candidates for further exploration in hypercholesterolemia therapy.
Conclusion: This study identifies repurposed compounds, particularly TAK-715 and Tyrphostin b46, as promising HMG-CoA reductase inhibitors. Their favorable profiles warrant further experimental validation for hypercholesterolemia treatment.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Work published in KMUJ is licensed under a
Creative Commons Attribution 4.0 License
Authors are permitted and encouraged to post their work online
(e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
1. Ahangari N, Mobarhan MG, Sahebkar A, Pasdar A. Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes. Ann Med 2018;50(4):303-11. https://doi.org/10.1080/07853890.2018.1457795
2. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J 2013;34(45):3478-90. https://doi.org/10.1093/eurheartj/eht273
3. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;14(1):111-88. https://doi.org/10.1093/eurheartj/ehz455
4. Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins - mechanisms and consequences. Curr Drug Saf 2009;4(3):209-28. https://doi.org/10.2174/157488609789006949
5. Ward NC, Watts GF, Eckel RH. Statin toxicity: mechanistic insights and clinical implications. Circ Res 2019;124(2):328-50. https://doi.org/10.1161/CIRCRESAHA.118.312782
6. Rajput TA, Naveed AK, Khan S, Farooqi ZUR. Frequencies of two functionally significant SNPs and their haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in six ethnic groups of Pakistani population. Iran J Basic Med Sci 2014;17(6):441-7.
7. Tromp TR, Hartgers ML, Hovingh GK, Vallejo-Vaz AJ, Ray KK, Soran H, et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet 2022;399(10326):719-28. https://doi.org/10.1016/S0140-6736(21)02001-8
8. Torre D, Krawczuk P, Jagodnik KM, Lachmann A, Wang Z, Wang L, et al. Datasets2Tools, repository and search engine for bioinformatics datasets, tools and canned analyses. Sci Data 2018;5(Dcic):1-10. https://doi.org/10.1038/sdata.2018.23
9. Cao Q, Liu Z, Xiong Y, Zhong Z, Ye Q. Multiple roles of 25-hydroxycholesterol in lipid metabolism, antivirus process, inflammatory response, and cell survival. Oxid Med Cell Longev 2020;2020:8893305. https://doi.org/10.1155/2020/8893305
10. Wu C, Zhao J, Li R, Feng F, He Y, Li Y, et al. Modulation of antiviral immunity and therapeutic efficacy by 25-hydroxycholesterol in chronically SIV-infected, ART-treated rhesus macaques. Virol Sin 2021;36(5):1197-1209. https://doi.org/10.1007/s12250-021-00407-6
11. Liu Y, Wei Z, Zhang Y, Ma X, Chen Y, Yu M, et al. Activation of liver X receptor plays a central role in antiviral actions of 25-hydroxycholesterol. J Lipid Res 2018;59(12):2287-96. https://doi.org/10.1194/jlr.M084558
12. Wang Y, Li X, Ren S. Cholesterol metabolites 25-hydroxycholesterol and 25-hydroxycholesterol 3-sulfate are potent paired regulators: from discovery to clinical usage. Metabolites 2021;11(1):1-14. https://doi.org/10.3390/metabo11010009
13. Eid BG, Abdel-Naim AB. Piceatannol attenuates testosterone-induced benign prostatic hyperplasia in rats by modulation of Nrf2/HO-1/NFκB axis. Front Pharmacol 2020;11(December):1-11. https://doi.org/10.3389/fphar.2020.614897
14. Tung YC, Lin YH, Chen HJ, Chou SC, Cheng AC, Kalyanam N, et al. Piceatannol exerts anti-obesity effects in C57BL/6 mice through modulating adipogenic proteins and gut microbiota. Molecules 2016;21(11):1419. https://doi.org/10.3390/molecules21111419
15. Chi Y, Li K, Yan Q, Koizumi S, Shi L, Takahashi S, et al. Nonsteroidal anti-inflammatory drug flufenamic acid is a potent activator of AMP-activated protein kinase. J Pharmacol Exp Ther 2011;339(1):257-66. https://doi.org/10.1124/jpet.111.183020
16. Al Rayyes O, Ahren B, Floren CH. Enhancement of low density lipoprotein catabolism by non-steroidal anti-inflammatory drugs in cultured HepG2 cells. Eur J Pharmacol 1999;372(3):311-8. https://doi.org/10.1016/S0014-2999(99)00246-0
17. Zasada M, Budzisz E. Retinoids: active molecules influencing skin structure formation in cosmetic and dermatological treatments. Postep Dermatologii i Alergol 2019;36(4):392-7. https://doi.org/10.5114/ada.2019.87443
18. Zhou W, Lin J, Chen H, Wang J, Liu Y, Xia M. Retinoic acid induces macrophage cholesterol efflux and inhibits atherosclerotic plaque formation in apoE-deficient mice. Br J Nutr 2015;114(4):509-18. https://doi.org/10.1017/S0007114515002159
19. He Y, Gong L, Fang Y, Zhan Q, Liu HX, Lu Y, et al. The role of retinoic acid in hepatic lipid homeostasis defined by genomic binding and transcriptome profiling. BMC Genomics 2013;14(1):1-11. https://doi.org/10.1186/1471-2164-14-575
20. Merwar G, Gibbons JR, Hosseini SA, Saadabadi A. Nortriptyline. 2023 Jun 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Availble from URL: https://www.ncbi.nlm.nih.gov/books/NBK482214/
21. Choung S, Kim JM, Joung KH, Lee ES, Kim HJ, Ku BJ. Epidermal growth factor receptor inhibition attenuates non-alcoholic fatty liver disease in diet-induced obese mice. PLoS One 2019;14(2):1-12. https://doi.org/10.1371/journal.pone.0210828
22. Miwatashi S, Arikawa Y, Kotani E, Miyamoto M, Naruo K, Kimura H, et al. Novel inhibitor of p38 MAP kinase as an anti-TNF-α drug: Discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J Med Chem 2005;48(19):5966-79. https://doi.org/10.1021/jm050165o
23. Willette RN, Eybye ME, Olzinski AR, Behm DJ, Aiyar N, Maniscalco K, et al. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J Pharmacol Exp Ther 2009;330(3):964-70. https://doi.org/10.1124/jpet.109.154443
24. O O'Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, et al. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial. JAMA 2016;315(15):1591-9. https://doi.org/10.1001/jama.2016.3609
25. Elkhawad M, Rudd JH, Sarov-Blat L, Cai G, Wells R, Davies LC, et al. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. JACC Cardiovasc Imaging 2012;5(9):911-22. https://doi.org/10.1016/j.jcmg.2012.02.016